ProMetic Life Sciences Inc. (TSX
LI) ("ProMetic") will present data on its orally-active PBI-1402 compound at the 15th Congress of the European Hematology Association held in Barcelona, Spain, June 9 - 13, 2010. Clinical and preclinical results will be presented about the management of side effects induced by chemotherapy and the treatment of certain cancers such as lung and pancreatic cancers, and certain forms of leukemia. In addition, an oral presentation will be made regarding the positive clinical data generated in patients that developed anemia as a result of their chemotherapy...
More...
LI) ("ProMetic") will present data on its orally-active PBI-1402 compound at the 15th Congress of the European Hematology Association held in Barcelona, Spain, June 9 - 13, 2010. Clinical and preclinical results will be presented about the management of side effects induced by chemotherapy and the treatment of certain cancers such as lung and pancreatic cancers, and certain forms of leukemia. In addition, an oral presentation will be made regarding the positive clinical data generated in patients that developed anemia as a result of their chemotherapy...More...